Literature DB >> 8307570

Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation.

B Plougastel1, J Zucman, M Peter, G Thomas, O Delattre.   

Abstract

The EWS gene has been identified based on its location at the chromosome 22 breakpoint of the t(11;22)(q24;q12) translocation that characterizes Ewing sarcoma and related neuroectodermal tumors. The EWS gene spans about 40 kb of DNA and is encoded by 17 exons. The nucleotide sequence of the exons is identical to that of the previously described cDNA. The first 7 exons encode the N-terminal domain of EWS, which consists of a repeated degenerated polypeptide of 7 to 12 residues rich in tyrosine, serine, threonine, glycine, and glutamine. Exons 11, 12, and 13 encode the putative RNA binding domain. The three glycine- and arginine-rich motifs of the gene are mainly encoded by exons 8-9, 14, and 16. The DNA sequence in the 5' region of the gene has features of a CpG-rich island and lacks canonical promoter elements, such as TATA and CCAAT consensus sequences. Positions of the chromosome 22 breakpoints were determined for 19 Ewing tumors. They were localized in introns 7 or 8 in 18 cases and in intron 10 in 1 case.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8307570     DOI: 10.1016/s0888-7543(05)80363-5

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  29 in total

1.  Dual transforming activities of the FUS (TLS)-ERG leukemia fusion protein conferred by two N-terminal domains of FUS (TLS).

Authors:  H Ichikawa; K Shimizu; R Katsu; M Ohki
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

Review 2.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

3.  Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas.

Authors:  Neerav N Shukla; Juber A Patel; Heather Magnan; Ahmet Zehir; Daoqi You; Jiabin Tang; Fanli Meng; Aliaksandra Samoila; Emily K Slotkin; Srikanth R Ambati; Alexander J Chou; Leonard H Wexler; Paul A Meyers; Ellinor I Peerschke; Agnes Viale; Michael F Berger; Marc Ladanyi
Journal:  JCO Precis Oncol       Date:  2017-05-23

4.  Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.

Authors:  J A Toretsky; Y Connell; L Neckers; N K Bhat
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

5.  Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma.

Authors:  R I Brody; T Ueda; A Hamelin; S C Jhanwar; J A Bridge; J H Healey; A G Huvos; W L Gerald; M Ladanyi
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

6.  Neurogenic potential of Ewing's sarcoma cells.

Authors:  T Sugimoto; A Umezawa; J Hata
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

7.  Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors.

Authors:  Jacquelyn J Roth; Mariarita Santi; Lucy B Rorke-Adams; Brian N Harding; Tracy M Busse; Laura S Tooke; Jaclyn A Biegel
Journal:  Cancer Genet       Date:  2014-03-15

Review 8.  Soft tissue tumors associated with EWSR1 translocation.

Authors:  Salvatore Romeo; Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

9.  EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations.

Authors:  Robert Beck; Michael J Monument; W Scott Watkins; Richard Smith; Kenneth M Boucher; Joshua D Schiffman; Lynn B Jorde; R Lor Randall; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2012-06

10.  Identification of the RGG box motif in Shadoo: RNA-binding and signaling roles?

Authors:  Susan M Corley; Jill E Gready
Journal:  Bioinform Biol Insights       Date:  2008-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.